دورية أكاديمية
Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
| العنوان: | Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed |
|---|---|
| المؤلفون: | Citrome, Leslie, Juday, Timothy, Frech, Feride, Atkins, Norman |
| المصدر: | NYMC Faculty Publications |
| بيانات النشر: | Touro Scholar |
| سنة النشر: | 2021 |
| المجموعة: | Touro College & University System: Touro Scholar |
| مصطلحات موضوعية: | Acetamides, Adolescent, Adult, Azepines, Benzodiazepines, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Orexin Receptor Antagonists, Pyridines, Pyrimidines, Sleep, Sleep Initiation and Maintenance Disorders, Treatment Outcome, Triazoles, Young Adult, Zolpidem, Faculty, Medicine and Health Sciences |
| الوصف: | Objective: To describe lemborexant for the treatment of insomnia (DSM-5) in adults using number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH). Methods: Lemborexant data were obtained from two Phase 3 trials conducted 2016-2018. Efficacy was assessed using different categorical definitions for response, and tolerability was assessed by evaluating rates of adverse events (AEs). Direct comparisons were made with zolpidem extended release (ER), and indirect comparisons were made with other hypnotic agents, including suvorexant, doxepin, ramelteon, zolpidem immediate release, eszopiclone, zaleplon, and selected benzodiazepines, using data from published reports and regulatory documents. Results: Lemborexant had a clinically relevant magnitude of therapeutic effect, as evidenced by NNT values versus placebo as robust as 3 (95% CI, 2-3). In general, NNH values for lemborexant versus placebo were ≥ 10, suggesting that lemborexant is relatively tolerable. Somnolence was the most common AE, with NNH estimates of 28 (95% CI, 18-61) and 15 (95% CI, 11-22) for lemborexant 5 mg and 10 mg, respectively. Rates of discontinuation of lemborexant because of an AE were low, and for lemborexant 5 mg the rate was lower than that for placebo. LHH contrasting the statistically significant endpoint efficacy measures versus discontinuation because of an AE ranged from 13 to 54. NNT values for lemborexant were generally more robust than for zolpidem ER for the polysomnography and sleep diary outcomes. In indirect comparisons, NNT data for the other hypnotics demonstrated effect sizes that were generally similar to those for lemborexant. Conclusions: In Phase 3 trials, the benefit-risk ratio for lemborexant is favorable as measured by NNT, NNH, and LHH. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | https://touroscholar.touro.edu/nymc_fac_pubs/3196Test; https://pubmed.ncbi.nlm.nih.gov/34077032/?myncbishare=nymclibTest |
| DOI: | 10.4088/JCP.20m13795 |
| الإتاحة: | https://doi.org/10.4088/JCP.20m13795Test https://touroscholar.touro.edu/nymc_fac_pubs/3196Test https://pubmed.ncbi.nlm.nih.gov/34077032/?myncbishare=nymclibTest |
| رقم الانضمام: | edsbas.D042FA72 |
| قاعدة البيانات: | BASE |
| DOI: | 10.4088/JCP.20m13795 |
|---|